University of Chicago Medicine
Comprehensive Cancer Center
Chicago, IL
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
EXCALIBER - Maintenance
Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma
- CELMoD
- Post-Autologous Stem Cell Transplant
- Randomization
- Phase 3
Not yet accepting
inMMyCAR
A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma
- CAR T Cell
- BCMA
- Phase 1
- Has results
Accepting patients
MonumenTAL-1
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Bispecific Antibody
- GPRC5D
- Phase 2
Not yet accepting
MajesTEC-4
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
- Bispecific T Cell Engager (BiTE)
- Bispecific Antibody
- BCMA
- Phase 3
Accepting patients
Belantamab Mafodotin
Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients With Relapsed Multiple Myeloma
- Antibody Drug Conjugate (ADC)
- BCMA
- Quadruplet Therapy
- Phase 2
Accepting patients
Sonrotoclax (BGB-11417)
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- BCL-2 Inhibitor
- Phase 1/2
- Has results
Accepting patients
TRIgnite-1
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma
- T Cell
- Trispecific Antibody
- BCMA
- CD38
- Phase 1
- Has results
- T Cell Engager (TCE)
- Bispecific Antibody
- CD3
- BCMA
- Maintenance
- Randomization
- High Risk
- Phase 2
Accepting patients
Impact of Non-Profit on Patient Outcomes & Care
The Impact of a Non-Profit Cancer Advocacy Organization on Patient Reported Outcomes and Access to Care: A Multisite, Longitudinal Trial
- Randomization
- Observational Trial